Lyell Immunopharma
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 20181, the company develops next-generation cell therapies, including CAR T cell (chimeric antigen receptor therapies), using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374167681 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “Lyell Immunopharma” date of foundation (×1) · confidence 0.95 revision URL